> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pemgarda Authorized for Preventing Covid
- URL: https://www.fdaweb.com/pemgarda-authorized-for-preventing-covid/
- Published: 2024-03-22T12:00:00.000Z
- Updated: 2026-09-14T14:26:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156617

FDA has granted Invivyd an emergency use authorization for Pemgarda (pemivibart) and its use for pre-exposure prophylaxis of Covid-19 in certain adults and adolescents. Pemgarda is authorized for those who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an infected individual, and those who are immune compromised due to a medical condition or due to taking immunosuppressive medications or treatments.

Authorization was based on an immunobridging approach to determine if Pemgarda may be effective for preventing Covid. “Immunobridging is based on the relationship between neutralizing antibody titers and clinical efficacy identified with other human monoclonal antibodies against SARS-CoV-2,” an [agency release](https://www.fda.gov/media/177068/download?attachment&ref=fdaweb.com) says. “This includes adintrevimab, a monoclonal antibody like Pemgarda, and certain other monoclonal antibodies that were previously authorized for the prevention of Covid-19\. The serum neutralizing antibody titers of Pemgarda were consistent with the titer levels associated with efficacy in prior clinical trials of adintrevimab and certain other monoclonal antibody products.”